Payers Could Guarantee Biosimilar Market Share, FDA's Gottlieb Suggests

Commissioner worries that fewer drugs may enter market in some categories because of drug development costs, and offers some post-market strategies for encouraging biosimilar development.

US FDA Commissioner Scott Gottlieb is suggesting that biosimilar adoption – and development of future products – can be aided by payers setting aside a portion of sales that will go to biosimilars.

Speaking at the at the Sept. 18 Chasing Cancer Summit hosted by the Washington Post, Gottlieb was asked about the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Biosimilars

More from Biosimilars & Generics